Ghasemiyeh Parisa, Fazlinejad Rahil, Kiafar Mohammad Reza, Rasekh Shiva, Mokhtarzadegan Mohammad, Mohammadi-Samani Soliman
Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Front Pharmacol. 2024 Apr 2;15:1337282. doi: 10.3389/fphar.2024.1337282. eCollection 2024.
Melasma is a chronic hyperpigmentation skin disorder that is more common in the female gender. Although melasma is a multifactorial skin disorder, however, sun-exposure and genetic predisposition are considered as the main etiologic factors in melasma occurrence. Although numerous topical and systemic therapeutic agents and also non-pharmacologic procedural treatments have been considered in melasma management, however, the commonly available therapeutic options have several limitations including the lack of sufficient clinical effectiveness, risk of relapse, and high rate of unwanted adverse drug reactions. Recruitment of nanotechnology for topical drug delivery in melasma management can lead to enhanced skin penetration, targeted drug delivery to the site of action, longer deposition at the targeted area, and limit systemic absorption and therefore systemic availability and adverse drug reactions. In the current review, first of all, the etiology, pathophysiology, and severity classification of melasma have been considered. Then, various pharmacologic and procedural therapeutic options in melasma treatment have been discussed. Afterward, the usage of various types of nanoparticles for the purpose of topical drug delivery for melasma management was considered. In the end, numerous clinical studies and controlled clinical trials on the assessment of the effectiveness of these novel topical formulations in melasma management are summarized.
黄褐斑是一种慢性色素沉着性皮肤病,在女性中更为常见。尽管黄褐斑是一种多因素皮肤病,但日晒和遗传易感性被认为是黄褐斑发生的主要病因。尽管在黄褐斑治疗中已经考虑了多种局部和全身治疗药物以及非药物程序性治疗方法,然而,常用的治疗选择有几个局限性,包括临床疗效不足、复发风险以及不良药物反应发生率高。将纳米技术用于黄褐斑治疗中的局部药物递送可增强皮肤渗透、将药物靶向递送至作用部位、在靶向区域的沉积时间更长,并限制全身吸收,从而限制全身可用性和药物不良反应。在本综述中,首先考虑了黄褐斑的病因、病理生理学和严重程度分类。然后,讨论了黄褐斑治疗中的各种药物和程序性治疗选择。之后,考虑了使用各种类型的纳米颗粒进行黄褐斑治疗的局部药物递送。最后,总结了众多关于评估这些新型局部制剂在黄褐斑治疗中有效性的临床研究和对照临床试验。